The Japan Advantage: A New Era for Global Drug Development
Accelerate your pipeline through a newly integrated, all-Japan drug development ecosystem
Join ENSEMBLExJ and the National Cancer Center Japan at CIC Cambridge for an afternoon that could reshape how you think about your pipeline. This is not a market-entry seminar. This is a strategic briefing for biotechs, biopharma leaders, and investors who want to move faster, smarter, and with the right partners from day one.
ENSEMBLExJ represents something genuinely new: an integrated, all-Japan ecosystem that brings together academia, regulatory authorities, and government to support foreign biotechs at the earliest stages of clinical development.
Hear directly from the source how to include Japan early, unlock regulatory incentives, and access top-tier clinical sites and KOLs. Then, stay for one-on-one conversations with the partners who can get you in the door early. Come with questions. Leave with a strategy.
This event is for you if you are:
● A biotech or biopharma company focused on Phase 1–2 development without a Japan entity
● A clinical or business development leader evaluating your next market
● A CMO, CEO, founder, or investor looking to increase asset value through global partnerships
Agenda
1:30 Registration/Networking (30 min)
2:00 Opening Remarks (5 min)
Welcome Remarks by the Consul-General of Japan in Boston
Seiichiro Takahashi / Consul General of Japan in Boston
2:10 Expert Presentations (20 min)
Why Include Japan Early? (Pharma perspective)
P.K. Morrow, MD /Takeda Pharmaceuticals
A New Gateway to Japan for Global Biotech- ENSEMBLExJ
Hitomi Okuma, MD, PhD / ENSEMBLExJ, National Cancer Center Japan
How ENSEMBLExJ Supports You
Kazuki Sone, MD, PhD / ENSEMBLExJ, National Cancer Center Japan
Regulatory Perspectives & Incentives
Akihiro Ishiguro, PhD / Pharmaceuticals and Medical Devices Agency (PMDA) Washington D.C. Office
2:35 Panel Discussion (25 min)
3:00 Networking (90 min)
4:30 Close